drug · antibody drug conjugate
datopotamab deruxtecan
pre_registrationupdated 6mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
indications
indications
NSCLC
targets
DNA topoisomerase 1Tumor-associated calcium signal transducer 2
all catalysts(0)
nothing on the calendar yet
Trials studying datopotamab deruxtecan
- phase3Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- phase2Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- phase3Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- phase2Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- phase1First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
- phase2A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- phase2TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
News(10)
- FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classThe FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…fiercebiotech · 6d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 17d ago
- ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP saysAt the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Al…biospace · 28d ago
- Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestonePlus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…endpoints · 1mo ago
- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.biopharma_dive · 2mo ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 2mo ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 3mo ago
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 3mo ago
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 3mo ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that